Pfizer’s respiratory syncytial virus (RSV) vaccine Abrysvo has shown efficacy in immunocompromised adults, the pharma announced Monday. In substudy B of Pfizer’s ongoing Phase 3 MONeT trial, Abrysvo ...
Pfizer has officially thrown its hat in the weight-loss ring. The company’s GLP-1 receptor agonist, danuglipron, showed promise in an ongoing pharmacokinetic study, it announced Thursday. Pfizer plans ...
Pfizer generated free cash flow of $10.4 billion in the 12 months ending Sept. 30, 2025. During this period, the pharma giant ...
Pfizer has started a late-stage clinical trial to test a vaccine that aims to protect against Lyme disease, the drugmaker announced Monday. There are currently no vaccines approved in the United ...
Pfizer has added another chapter to its long-running drug discovery collaboration with Chinese tech startup XtalPi, this time upgrading their molecular modeling work. The aim is to help “grasp ...
Pfizer is making its largest-ever debt issuance. It's going to use the proceeds to acquire Seagen. The growth it'll likely experience will be foundational to the company's future. The pharmaceutical ...
British drugmaker GSK told Manhattan prosecutors that a former employee told colleagues Pfizer held back positive results until after the 2020 election. But the former employee, who worked at both ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback